Q1 2025 EPS Estimates for Halozyme Therapeutics, Inc. (NASDAQ:HALO) Increased by Zacks Research

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities researchers at Zacks Research boosted their Q1 2025 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a report released on Monday, September 23rd. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of $0.93 per share for the quarter, up from their previous forecast of $0.92. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.71 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $4.40 EPS, Q2 2026 earnings at $1.48 EPS and FY2026 earnings at $5.90 EPS.

A number of other research analysts have also weighed in on HALO. Benchmark reissued a “buy” rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. The Goldman Sachs Group lifted their price target on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a report on Monday, July 22nd. Morgan Stanley increased their price objective on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $65.00 target price on shares of Halozyme Therapeutics in a report on Friday, September 13th. Finally, Piper Sandler lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $48.00 to $51.00 in a report on Friday, June 7th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $60.00.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $56.20 on Wednesday. The company has a market capitalization of $7.12 billion, a price-to-earnings ratio of 23.22, a PEG ratio of 0.56 and a beta of 1.28. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41. Halozyme Therapeutics has a 1 year low of $32.83 and a 1 year high of $65.53. The company’s 50 day simple moving average is $58.54 and its 200 day simple moving average is $49.48.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The business had revenue of $231.40 million for the quarter, compared to analyst estimates of $204.94 million. During the same quarter last year, the company earned $0.68 earnings per share. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. TD Asset Management Inc boosted its holdings in shares of Halozyme Therapeutics by 28.1% in the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock valued at $103,379,000 after buying an additional 557,350 shares during the period. Congress Asset Management Co. MA grew its stake in Halozyme Therapeutics by 16.2% during the 1st quarter. Congress Asset Management Co. MA now owns 407,867 shares of the biopharmaceutical company’s stock worth $16,592,000 after buying an additional 56,791 shares during the last quarter. Boston Trust Walden Corp acquired a new stake in Halozyme Therapeutics in the second quarter worth $23,211,000. Los Angeles Capital Management LLC grew its position in shares of Halozyme Therapeutics by 17.2% during the first quarter. Los Angeles Capital Management LLC now owns 121,000 shares of the biopharmaceutical company’s stock worth $4,922,000 after acquiring an additional 17,716 shares during the last quarter. Finally, Norden Group LLC lifted its position in Halozyme Therapeutics by 1,817.3% in the 1st quarter. Norden Group LLC now owns 167,284 shares of the biopharmaceutical company’s stock valued at $6,805,000 after purchasing an additional 158,559 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $55.12, for a total value of $551,200.00. Following the completion of the transaction, the senior vice president now owns 168,176 shares of the company’s stock, valued at $9,269,861.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $55.12, for a total value of $551,200.00. Following the completion of the sale, the senior vice president now owns 168,176 shares in the company, valued at $9,269,861.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total transaction of $570,133.70. Following the transaction, the director now directly owns 69,874 shares of the company’s stock, valued at $4,031,729.80. The disclosure for this sale can be found here. Insiders sold a total of 84,881 shares of company stock valued at $4,888,184 in the last ninety days. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.